- Report
- December 2024
- 150 Pages
Global
From €5243EUR$5,950USD£4,605GBP
- Report
- July 2025
- 150 Pages
Global
From €5243EUR$5,950USD£4,605GBP
- Report
- October 2025
- 198 Pages
Global
From €3124EUR$3,545USD£2,744GBP
€3471EUR$3,939USD£3,049GBP
- Report
- August 2025
- 194 Pages
Global
From €3124EUR$3,545USD£2,744GBP
€3471EUR$3,939USD£3,049GBP
- Report
- October 2025
- 250 Pages
Global
From €3957EUR$4,490USD£3,475GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1410EUR$1,600USD£1,238GBP
€1762EUR$2,000USD£1,548GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €1762EUR$2,000USD£1,548GBP
€2203EUR$2,500USD£1,935GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €881EUR$1,000USD£774GBP
€1102EUR$1,250USD£968GBP
- Report
- December 2025
- 281 Pages
Global
From €5155EUR$5,850USD£4,528GBP
- Report
- December 2025
- 364 Pages
Global
From €5155EUR$5,850USD£4,528GBP
- Report
- August 2025
- 189 Pages
Global
From €3124EUR$3,545USD£2,744GBP
€3471EUR$3,939USD£3,049GBP
- Report
- April 2025
- 183 Pages
Global
From €3965EUR$4,500USD£3,483GBP
- Report
- October 2025
- 150 Pages
Global
From €3393EUR$3,850USD£2,980GBP
- Report
- January 2025
- 200 Pages
Global
From €4402EUR$4,995USD£3,866GBP
- Report
- August 2025
- 120 Pages
United States
From €3481EUR$3,950USD£3,057GBP
- Report
- November 2018
- 147 Pages
Global
From €2423EUR$2,750USD£2,129GBP
- Report
- October 2023
- 145 Pages
Global
From €2776EUR$3,150USD£2,438GBP
- Report
- October 2023
- 145 Pages
Global
From €2776EUR$3,150USD£2,438GBP
- Report
- December 2024
- 84 Pages
Global
From €2785EUR$3,160USD£2,446GBP
€3481EUR$3,950USD£3,057GBP
- Report
- February 2024
- 168 Pages
Global
From €5604EUR$6,360USD£4,923GBP
€7006EUR$7,950USD£6,153GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more